CD274 and neoplasm: The ability of avelumab to mediate ADCC of tumor cells versus peripheral immune cells was conducted in controlled in vitro experiments using NK cells as effectors from healthy donors and cancer patients and showed that avelumab can mediate ADCC of PD-L1 expressing tumor cells, but not against PD-L1 expressing immune cells [110].